Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations.

Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW.

Pigment Cell Melanoma Res. 2016 Sep;29(5):590-7. doi: 10.1111/pcmr.12498. Epub 2016 Aug 3.

2.

Ascophyllan functions as an adjuvant to promote anti-cancer effect by dendritic cell activation.

Zhang W, Okimura T, Xu L, Zhang L, Oda T, Kwak M, Yu Q, Jin JO.

Oncotarget. 2016 Apr 12;7(15):19284-98. doi: 10.18632/oncotarget.8200.

3.

Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis.

Das SK, Guo C, Pradhan AK, Bhoopathi P, Talukdar S, Shen XN, Emdad L, Subler MA, Windle JJ, Sarkar D, Wang XY, Fisher PB.

Oncotarget. 2016 Jul 26;7(30):46848-46861. doi: 10.18632/oncotarget.10040.

4.

N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.

Ishii-Osai Y, Yamashita T, Tamura Y, Sato N, Ito A, Honda H, Wakamatsu K, Ito S, Nakayama E, Okura M, Jimbow K.

J Dermatol Sci. 2012 Jul;67(1):51-60. doi: 10.1016/j.jdermsci.2012.04.009. Epub 2012 May 2.

PMID:
22622238
5.

Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors.

Combest AJ, Roberts PJ, Dillon PM, Sandison K, Hanna SK, Ross C, Habibi S, Zamboni B, Müller M, Brunner M, Sharpless NE, Zamboni WC.

Oncologist. 2012;17(10):1303-16. doi: 10.1634/theoncologist.2012-0274. Epub 2012 Sep 19.

6.
7.

IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process.

Le Coz V, Zhu C, Devocelle A, Vazquez A, Boucheix C, Azzi S, Gallerne C, Eid P, Lecourt S, Giron-Michel J.

Oncotarget. 2016 Dec 13;7(50):82511-82527. doi: 10.18632/oncotarget.12733.

8.

Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma.

Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita M.

Gene Ther. 2011 Aug;18(8):827-34. doi: 10.1038/gt.2011.28. Epub 2011 Mar 10.

9.

The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.

Yamamura Y, Tsuchikawa T, Miyauchi K, Takeuchi S, Wada M, Kuwatani T, Kyogoku N, Kuroda A, Maki T, Shichinohe T, Hirano S.

Int J Clin Oncol. 2015 Apr;20(2):386-94. doi: 10.1007/s10147-014-0719-x. Epub 2014 Jun 28.

PMID:
24972573
10.

FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.

Pereira FV, Arruda DC, Figueiredo CR, Massaoka MH, Matsuo AL, Bueno V, Rodrigues EG.

Clinics (Sao Paulo). 2013 Jul;68(7):1018-27. doi: 10.6061/clinics/2013(07)21.

11.

The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.

Cho JH, Lee HJ, Ko HJ, Yoon BI, Choe J, Kim KC, Hahn TW, Han JA, Choi SS, Jung YM, Lee KH, Lee YS, Jung YJ.

Oncotarget. 2017 Apr 11;8(15):24932-24948. doi: 10.18632/oncotarget.15326.

12.

Multidrug resistance decreases with mutations of melanosomal regulatory genes.

Xie T, Nguyen T, Hupe M, Wei ML.

Cancer Res. 2009 Feb 1;69(3):992-9. doi: 10.1158/0008-5472.CAN-08-0506. Epub 2009 Jan 20.

13.

A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.

Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE Jr, Sampson JH, Priebe W, Heimberger AB.

Clin Cancer Res. 2008 Sep 15;14(18):5759-68. doi: 10.1158/1078-0432.CCR-08-0377.

14.

Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment.

Wang S, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM.

Cancer Immunol Immunother. 2012 Jan;61(1):49-61. doi: 10.1007/s00262-011-1090-7. Epub 2011 Aug 13.

15.

Establishment and characterization of cell lines from chromosomal instable colorectal cancer.

Maletzki C, Gock M, Randow M, Klar E, Huehns M, Prall F, Linnebacher M.

World J Gastroenterol. 2015 Jan 7;21(1):164-76. doi: 10.3748/wjg.v21.i1.164.

16.

Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma.

De Stefano I, Raspaglio G, Zannoni GF, Travaglia D, Prisco MG, Mosca M, Ferlini C, Scambia G, Gallo D.

Biochem Pharmacol. 2009 Dec 1;78(11):1374-81. doi: 10.1016/j.bcp.2009.07.011. Epub 2009 Jul 28.

PMID:
19643088
17.

Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.

Mahvi DA, Meyers JV, Tatar AJ, Contreras A, Suresh M, Leverson GE, Sen S, Cho CS.

J Immunother. 2015 Feb-Mar;38(2):54-61. doi: 10.1097/CJI.0000000000000064.

18.

Syngeneic murine metastasis models: B16 melanoma.

Giavazzi R, Decio A.

Methods Mol Biol. 2014;1070:131-40. doi: 10.1007/978-1-4614-8244-4_10.

PMID:
24092437
19.

Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.

Goncharova EP, Ruzhenkova JS, Petrov IS, Shchelkunov SN, Zenkova MA.

J Transl Med. 2016 Aug 18;14(1):241. doi: 10.1186/s12967-016-1002-x. Erratum in: J Transl Med. 2016;14(1):280.

20.

Supplemental Content

Support Center